#1 Clinical Trials Search in Europe

Glucagon

Glucagon, a hormone that plays a crucial role in regulating blood sugar levels, has been the subject of numerous clinical trials aimed at improving diabetes management. These studies investigate various aspects of glucagon administration, including new delivery methods, its effectiveness in preventing hypoglycemia, and its potential impact on energy expenditure and lipoprotein production. The research spans across different patient groups, from adults to children with type 1 diabetes, and even explores its use in obesity treatment.

Table of Contents

What is Glucagon?

Glucagon is a hormone that plays a crucial role in regulating blood sugar levels in the body. It is naturally produced by the pancreas, but it can also be manufactured as a medication to treat certain medical conditions[1]. Glucagon is often referred to as the “opposing hormone” to insulin, as it helps raise blood sugar levels when they are too low[2].

Uses of Glucagon

The primary use of glucagon as a medication is to treat severe hypoglycemia (very low blood sugar) in people with diabetes, particularly those with Type 1 Diabetes Mellitus[3]. Hypoglycemia can be a dangerous condition that may lead to unconsciousness if not treated promptly. Some other uses and potential applications of glucagon include:

  • Preventing exercise-induced hypoglycemia in people with Type 1 Diabetes[4]
  • Regulating blood sugar levels as part of an artificial pancreas or closed-loop insulin delivery system[5]
  • Potentially aiding in weight loss and obesity management (currently under research)[6]

How Glucagon Works

When glucagon is administered, it triggers the liver to release stored glucose (sugar) into the bloodstream. This process is called glycogenolysis. Glucagon also stimulates the production of new glucose in the liver, a process known as gluconeogenesis. These actions help to quickly raise blood sugar levels[2].

Forms of Glucagon

Glucagon is available in several forms, each designed for different situations:

  • Injectable Glucagon: Traditional form, often used in emergency kits (e.g., GlucaGen®)[7]
  • Nasal Glucagon: A needle-free option that can be administered through the nose[3]
  • Auto-Injector Glucagon: Pre-mixed liquid glucagon in an easy-to-use auto-injector (e.g., G-Pen™)[1]
  • Microneedle Patch: A transdermal patch system for glucagon delivery (e.g., ZP-Glucagon)[8]

Administration and Dosage

The dosage of glucagon varies depending on the patient’s age, the severity of hypoglycemia, and the form of glucagon being used. For example:

  • Adults and children 12 years and older typically receive a 1 mg dose[9]
  • Children under 12 years old may receive a 0.5 mg dose[9]
  • For prevention of exercise-induced hypoglycemia, smaller doses (e.g., 150 μg) may be used[4]

It’s important to follow the instructions provided with the specific glucagon product and consult with a healthcare provider for proper usage.

Effectiveness

Glucagon is highly effective in raising blood glucose levels quickly. Studies have shown that it can increase blood sugar to safe levels within 10-15 minutes of administration in most cases[7]. The effectiveness is measured by:

  • How quickly blood glucose levels rise
  • The percentage of patients achieving normal blood sugar levels within a specific timeframe
  • The overall change in blood glucose levels over time

Safety and Side Effects

Glucagon is generally considered safe when used as directed. However, like all medications, it can have side effects. Common side effects may include:

  • Nausea and vomiting
  • Headache
  • Dizziness
  • Injection site reactions (for injectable forms)

Serious side effects are rare but can include allergic reactions. It’s important to seek medical attention if severe side effects occur[3].

Ongoing Research

Researchers are continually studying glucagon to improve its formulation, delivery methods, and potential new uses. Some areas of ongoing research include:

  • Development of stable liquid glucagon formulations for easier use in emergencies[1]
  • Investigating the use of glucagon in dual-hormone artificial pancreas systems[5]
  • Exploring the potential of glucagon in weight management and obesity treatment[6]
  • Studying the effects of repeated glucagon doses on liver glycogen stores[5]

These ongoing studies aim to expand our understanding of glucagon and potentially broaden its therapeutic applications in the future.

Aspect Details
New Delivery Methods Nasal sprays, microneedle patches, auto-injectors
Hypoglycemia Prevention Low-dose glucagon before exercise, use in closed-loop systems
Patient Groups Adults and children with Type 1 Diabetes, obese individuals
Other Applications Energy expenditure in obesity, lipoprotein production regulation
Safety Considerations Effects of repeated doses on liver glycogen stores
Measurement Techniques 13C MRS for hepatic glycogen quantification, plasma glucose and glucagon monitoring

FAQ

  • What is glucagon and how is it used in diabetes management? Glucagon is a hormone that raises blood sugar levels. In diabetes management, it's primarily used to treat severe hypoglycemia (low blood sugar). Recent clinical trials are exploring new ways to use glucagon, such as in preventing hypoglycemia and in novel delivery methods like nasal sprays and microneedle patches.
  • Are there new methods being developed for glucagon administration? Yes, several clinical trials are investigating new methods for glucagon administration. These include nasal glucagon sprays, microneedle patch systems, and auto-injectors. These new methods aim to provide easier, faster, and more convenient ways to deliver glucagon, especially in emergency situations.
  • Can glucagon be used to prevent hypoglycemia during exercise in people with type 1 diabetes? Clinical trials are exploring the use of low-dose glucagon to prevent exercise-induced hypoglycemia in people with type 1 diabetes. One study is specifically looking at administering a small dose of glucagon before aerobic exercise to see if it can help maintain blood sugar levels.
  • Is glucagon being studied for any purposes other than treating hypoglycemia? Yes, glucagon is being studied for various other purposes. Some trials are investigating its potential effects on energy expenditure in obese individuals, while others are looking at its role in regulating lipoprotein production in the liver and intestines. These studies may lead to new applications for glucagon beyond hypoglycemia treatment.
  • Are there any concerns about the repeated use of glucagon? While glucagon is generally safe for emergency use, some studies are investigating the effects of repeated glucagon doses. One concern is whether frequent use could deplete liver glycogen stores, which could potentially increase the risk of severe hypoglycemia. Researchers are using advanced imaging techniques to study this potential effect.

Ongoing Clinical Trials on Glucagon

  • Using glucagon and automated insulin delivery to prevent low blood sugar during exercise in adults with type 1 diabetes

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study of glucagon effects on physical capacity in patients with heart failure with preserved ejection fraction (HFpEF) with or without liver steatosis

    Recruiting

    1 1
    Investigated drugs:
    Germany

  • Study on the Impact of [18F]-AlF-FAPI-74, Glucagon, and Hyoscine Butylbromide in Patients with Resectable Biliary Tract Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Use of 18F-PSMA-1007, Hyoscine Butylbromide, and Gadoteric Acid in Imaging for Patients with High-Risk Prostate Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • A study evaluating a combination of glucagon and insulin lispro to improve insulin absorption in adults with Type 1 diabetes

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Romania

  • Study on Glucagon and Insulin for Improving Insulin Absorption in Patients with Type 1 Diabetes

    Not recruiting

    1 1 1
    Investigated drugs:
    Norway

  • Study of AZD9550 and AZD6234 combination for weight loss in people with obesity or overweight with health complications

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Safety and Effects of AZD9550 for Overweight and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) with or without Type 2 Diabetes

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Sweden

Glossary

  • Glucagon: A hormone produced by the pancreas that raises blood sugar levels. It's used medically to treat severe hypoglycemia in people with diabetes.
  • Hypoglycemia: A condition characterized by abnormally low blood sugar levels, which can be dangerous for people with diabetes.
  • Type 1 Diabetes: A chronic condition in which the pancreas produces little or no insulin, requiring lifelong insulin therapy.
  • Insulin: A hormone that allows cells to use glucose from the bloodstream for energy or storage.
  • Microneedle patch: A drug delivery system that uses tiny needles to administer medication through the skin.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body.
  • Lipoprotein: A combination of lipids (fats) and proteins that helps transport fats through the bloodstream.
  • Glycogen: A form of stored glucose in the liver and muscles, which can be broken down to raise blood sugar levels when needed.
  • Closed-loop system: An automated insulin delivery system that adjusts insulin doses based on continuous glucose monitoring data.

References

  1. https://clinicaltrials.gov/study/NCT01972152
  2. https://clinicaltrials.gov/study/NCT01155206
  3. https://clinicaltrials.gov/study/NCT03339453
  4. https://clinicaltrials.gov/study/NCT05379686
  5. https://clinicaltrials.gov/study/NCT01986231
  6. https://clinicaltrials.gov/study/NCT03139305
  7. https://clinicaltrials.gov/study/NCT02660008
  8. https://clinicaltrials.gov/study/NCT02459938
  9. https://clinicaltrials.gov/study/NCT03091673